CX-904 is an investigational, masked, conditionally activated PROBODY T-cell engager designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells ...

A long-time factor for a medical test for kidney transplant evaluations has been rectified, which has lessened a massive ...

The first article, "Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)" describes a ...

Biomarker tests can help your doctor learn more about the type of lung cancer you have and the best way to treat it.

Lung cancer is the world’s leading cause of death due to cancer according to the World Health Organization.1 Thus an urgent ...

Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research (“AACR”) Annual ...

Second, implementing eGFR or CrCl rather than sCr thresholds to determine individual eligibility for metformin could considerably expand the population eligible for its use, particularly among non ...

Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -- First dose ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The American Society for Bone and Mineral Research Task ...

Stage 3 CKD indicates your kidneys have mild to moderate damage, based on lab results. At this stage, you may start to notice symptoms of CKD, including frequent urination and changes to the color ...

Updated guidelines for small cell lung cancer were developed with an expert panel assembled by the American Society of ...

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trialZeno BLA accepted for priority review by th ...